sorafenib has been researched along with melitten in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (melitten) | Trials (melitten) | Recent Studies (post-2010) (melitten) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 2,121 | 4 | 581 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelhamid, IA; El-Magd, MA; Elzayat, EM; Hady A Abdel Wahab, A; Ibrahim, NS; Mahfouz, DH; Mansour, GH; Mohamed, MF | 1 |
1 other study(ies) available for sorafenib and melitten
| Article | Year |
|---|---|
Bee venom and its active component Melittin synergistically potentiate the anticancer effect of Sorafenib against HepG2 cells.
Topics: Antineoplastic Agents; Bee Venoms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Hep G2 Cells; Humans; Lipid Peroxidation; Melitten; Molecular Docking Simulation; Molecular Structure; Sorafenib; Structure-Activity Relationship; Tumor Cells, Cultured | 2021 |